Update: Cancer Immunotherapy Biotech Files for Insolvency
Update (06/12/2019): Following the phase III failure of its immunotherapy drug for colorectal cancer in…
Update (06/12/2019): Following the phase III failure of its immunotherapy drug for colorectal cancer in…
The vibrant startup scene of the German capital has attracted many biotechs to make it…
Today, March 8, is international women's day. To celebrate the achievements of women we're revisiting…
Mariola Söhngen, CEO of Mologen, discusses biotech entrepreneurship in Germany and her company's unique immunotherapy…
This infographic gathers 10 of the best HIV treatments in Europe's pipeline that will help…
Update (17/02/2017): Mologen has announced more positive data for lefitolimod in HIV, as the Danish Aarhus…
MD Anderson (US) and the Berlin Biotech Mologen (Germany) have now partnered on for an Immuno-Oncology program fighting…
This week, we're leaving Paris and heading East to a city that's 9 times bigger than…